153 related articles for article (PubMed ID: 2893360)
1. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
2. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
Chiu S; Paulose CS; Mishra RK
Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
[TBL] [Abstract][Full Text] [Related]
4. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
Bhargava HN
Neuropharmacology; 1984 Apr; 23(4):439-44. PubMed ID: 6145116
[TBL] [Abstract][Full Text] [Related]
5. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Chiu S; Paulose CS; Mishra RK
Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
[TBL] [Abstract][Full Text] [Related]
6. Modulation of CNS dopamine receptors by peptides.
Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):437-42. PubMed ID: 6141599
[TBL] [Abstract][Full Text] [Related]
7. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
Kostrzewa RM; Saleh MI
Neuropharmacology; 1989 Aug; 28(8):805-10. PubMed ID: 2571103
[TBL] [Abstract][Full Text] [Related]
9. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
10. L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.
Ott MC; Costain WJ; Mishra RK; Johnson RL
Peptides; 2000 Feb; 21(2):301-8. PubMed ID: 10764960
[TBL] [Abstract][Full Text] [Related]
11. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
[TBL] [Abstract][Full Text] [Related]
12. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
[TBL] [Abstract][Full Text] [Related]
13. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
14. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny.
Saleh MI; Kostrzewa RM
Peptides; 1989; 10(1):35-9. PubMed ID: 2568624
[TBL] [Abstract][Full Text] [Related]
15. Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
Prasad C; Spahn SA; Ikegami H
Biochem Biophys Res Commun; 1989 Feb; 159(1):48-52. PubMed ID: 2522303
[TBL] [Abstract][Full Text] [Related]
16. Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
Koller WC
J Clin Psychopharmacol; 1984 Dec; 4(6):343-5. PubMed ID: 6512004
[TBL] [Abstract][Full Text] [Related]
17. Striatal dopamine receptor supersensitivity after long-term haloperidol treatment of hypophysectomized rats.
DeLucia R; Scavone C; Camillo MA
Braz J Med Biol Res; 1989; 22(6):741-3. PubMed ID: 2620186
[TBL] [Abstract][Full Text] [Related]
18. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
Mishra RK
Nutr Health; 1984; 3(3):175-87. PubMed ID: 6152723
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
Johnson RL; Rajakumar G; Mishra RK
J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
[TBL] [Abstract][Full Text] [Related]
20. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
Friedhoff AJ; Bonnet K; Tosengarten H
Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
